Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
AngioDynamics, Inc. develops, manufactures and sells medical technology devices used by professional healthcare providers in vascular disease, oncology and surgical settings. The company’s recurring updates center on its Med Tech portfolio, including AlphaVac and AngioVac mechanical thrombectomy products, Auryon, and the NanoKnife System for irreversible electroporation-based tumor ablation.
Company news also covers fiscal earnings, guidance changes, product adoption, reimbursement and coding topics, FDA clearances and investigational device exemptions, and expanded European indications for NanoKnife across liver, pancreas, kidney and prostate tumors. Other recurring items include pulmonary embolism research initiatives, cardiovascular scientific forums, investor conference presentations and portfolio changes following completed divestitures and discontinued product lines.
AngioDynamics (NASDAQ: ANGO) reported its third-quarter fiscal 2021 financial results, showing a 2% year-over-year revenue growth to $71.2 million, despite COVID-19 challenges. Vascular Interventions and Therapies sales increased by 8.8% to $33.3 million. However, Oncology sales dropped by 10.1% to $13.1 million. The company recorded a net loss of $3.5 million, improving from a $5.7 million loss last year. The gross margin declined to 54.1% due to Auryon start-up costs and COVID-related impacts. Adjusted guidance for FY2021 is now $285-$288 million in sales.
AngioDynamics (NASDAQ: ANGO) announced that CEO Jim Clemmer and CFO Stephen Trowbridge will take part in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum. The event is scheduled for 10:00 a.m. ET on March 24, 2021. Investors can access a live webcast through the company’s website, with replay availability post-event. AngioDynamics specializes in minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, offering a range of leading products.
AngioDynamics, Inc. (NASDAQ: ANGO) announces participation in a virtual fireside chat at the 31st Annual Oppenheimer Healthcare Conference. Scheduled for March 16, 2021, at 9:20 a.m. ET, CEO Jim Clemmer and CFO Stephen Trowbridge will discuss company insights. A live webcast will be available through the Company’s website, with replay options post-event. AngioDynamics specializes in innovative, minimally invasive medical devices for vascular access, oncology, and peripheral vascular disease, focusing on diverse product lines that enhance patient care.
AngioDynamics, Inc. (NASDAQ: ANGO) will report its financial results for Q3 FY2021 on March 30, 2021, before the market opens. Management will host a conference call at 8:00 a.m. ET to discuss these results. Interested participants can join by calling 1-877-407-0784 domestically or +1-201-689-8560 internationally, using passcode 13717367. The call will also be available via webcast on the AngioDynamics website, with a replay accessible shortly after the call concludes.
AngioDynamics, a leader in minimally invasive medical devices, has announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the Barclays Virtual Global Healthcare Conference on March 9, 2021, at 8:00 a.m. ET. Investors can access a live webcast of the presentation through the Company’s website, with a replay available later. AngioDynamics specializes in devices for vascular access, peripheral vascular disease, and oncology, offering a range of products including ablation systems and thrombolytic products.
AngioDynamics, Inc. (NASDAQ: ANGO) has appointed Richard C. Rosenzweig as Senior Vice President and General Counsel effective January 31, 2021. He succeeds Stephen Trowbridge, who will continue as Chief Financial Officer. Additionally, Juan Carlos Serna has been promoted to Senior Vice President of Scientific and Clinical Affairs, overseeing key teams for advancing scientific research and patient access. Both appointments are seen as strategic moves to enhance leadership and drive growth in AngioDynamics' medical technologies.
AngioDynamics reported Q2 fiscal 2021 results showing net sales of $72.8 million, up 4% year-over-year despite COVID-19 disruptions. Growth in Vascular Interventions and Therapies was driven by AngioVac sales, which rose 8.8%. However, net loss increased to $4.3 million or $0.11 per share. Gross margin declined to 55.2%, largely due to COVID-related operating costs. For the six months ending November 30, total sales were $143 million, up 5.1%. The company maintains a fiscal 2021 sales guidance of $278 to $284 million.
AngioDynamics, Inc. (NASDAQ: ANGO) has announced that Jim Clemmer, President and CEO, along with Stephen Trowbridge, Executive VP and CFO, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference at 2:50 p.m. ET on January 14, 2021.
A live webcast will be available in the 'Investors' section of AngioDynamics' website, with a replay accessible after the event. AngioDynamics specializes in innovative, minimally invasive medical devices focused on vascular access, peripheral vascular disease, and oncology.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the 23rd Annual Needham Virtual Growth Conference on January 11, 2021, at 1:15 p.m. ET. The presentation will be streamed live on the company's website, with a replay available afterward. AngioDynamics specializes in minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, featuring a diverse range of products including ablation and vascular access systems.
AngioDynamics, Inc. (NASDAQ: ANGO) will report its financial results for the second quarter of fiscal 2021 on January 7, 2021, before the market opens. A conference call to discuss these results will take place at 8:00 a.m. ET on the same day, with participation options available via phone and webcast. AngioDynamics specializes in innovative, minimally invasive medical devices for vascular access, oncology, and peripheral vascular disease, with a diverse range of products including ablation systems and drainage products.